Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,138.80
(
-0.49%
)
US TECH 100
26,396.40
(
0.36%
)
Dow Jones
0.00
(
0.00%
)
Brent Oil
107.09
(
2.56%
)
Bitcoin
77,677.06
(
1.74%
)
News Focus
News Focus

Replies to post #189 on Cardiol Therapeutics Inc (CRDL)

Replies to #189 on Cardiol Therapeutics Inc (CRDL)
icon url

MahinAgency

10/23/24 11:06 AM

#194 RE: jobynimble #189

NASDAQ: $CRDL is advancing CardiolRx for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million, with key trial results due in November 2024?
Bullish
Bullish
icon url

MahinAgency

10/23/24 1:32 PM

#195 RE: jobynimble #189

NASDAQ: $CRDL is advancing CardiolRx for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million, with key trial results due in November 2024?
icon url

MahinAgency

11/15/24 1:46 PM

#236 RE: jobynimble #189

NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

 Valued at $9 per share, assuming $609M in sales by 2033

Valued at $1 per share, assuming $132M in sales by 2033
Bullish
Bullish